General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases; Medication affordability and access.
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to drug importation in general; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act;
Duration: July 16, 2009
to
March 31, 2020
General Issues: Health Issues , Budget/Appropriations , Medicare/Medicaid , Pharmacy , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Defense , Foreign Relations , Veterans , Constitution
Spending: about $2,580,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Natl Economic Council (NEC), U.S. Trade Representative (USTR), U.S. Senate,, House of Representatives,, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Mark Rayder Leg. Ass't Rep. T. Latham; Leg. Ass't Rep. R. Frelinghuysen
District Rep. D. Gallo
Laura Holland Legislative Aide to Rep. Nathan Deal
Elinor Hiller Senior Advisor, Office of the Administrator, CMS; Director, Medicare Parts C and D Analysis Group, Office of Legislation, CMS.
Bob Siggins Chief of Staff for Rep. Earl Pomeroy
Marilyn Yager Dep. Ass't to the Pres., W.H. Office of Pub. Liason
Colin Roskey Health Policy Adv'r & Counsel, Sen. Finance Cmte
Earl Pomeroy U.S. Congressman (North Dakota)
Danielle White Intern, Senate HELP Committee; Intern, HHS Office of General Counsel (CMS Division); Intern, Rep. Nancy Johnson; Staff Assistant, Rep. Nancy Johnson; Executive Assistant, Rep. Nancy Johnson.
Y. Brian Lee Legislative Intern, Rep. Doug Lamborn.
Peter Fise Staff Ass't, House Oversight & Gov't Reform Cmte
Michael Park Health Policy Counsel, Senate Finance Committee
Mary Langowski Prof. Staff, Senate Agriculture Committee
Peter J. Eckrich LA, Sen. Mike Rounds; LA, Rep. Kristi Noem.
Carolyn Smith Associate Deputy Chief of Staff & Legislative Counsel, Joint Committee on Tax
Jane Lucas Special Assistant to the President, White House Office of Legislative Affairs; Principal Deputy Director, IOS-Office of Health Reform, HHS; Legislative Director, Sen. John Thune (R-SD). All lobbying activities conducted in compliance with EO 13770.
Keavney Klein n/a
Regina Sherick n/a
Joyce Gresko n/a
Timothy P. Trysla n/a
Shannon Campagna n/a
Stephanie Curtis n/a
Caitlin Maloney n/a
Tim Trysla n/a
Tamara Tenney n/a
Emily A. Shaw n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2020
ALSTON & BIRD LLP terminated an engagement in which they represented Novo Nordisk Inc. on April 20, 2020.
Original Filing: 301178821.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases; Medication affordability and access.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to drug importation in general; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act;
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127111.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
ALSTON & BIRD LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q32019 on Nov. 8, 2019.
Original Filing: 301081091.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077996.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
ALSTON & BIRD LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q22019 on Nov. 8, 2019.
Original Filing: 301081089.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 22, 2019.
Original Filing: 301057909.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; S. 1948/H.R. 3709, Chronic Disease Management Act; issues related to high deductible health plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to the scoring of Preventive Health Savings Act, H.R. 2584/S. 1361.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
ALSTON & BIRD LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q12019 on Nov. 8, 2019.
Original Filing: 301081087.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to CBO scoring of preventive health services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 22, 2019.
Original Filing: 301036719.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to CBO scoring of preventive health services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301016546.xml
Lobbying Issues
General diabetes prevention; medication affordability and access; H.R. 4978/S. 2410, Chronic Disease Management Act of 2018; National Obesity Care Week.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations), and FY19 Labor, Health and Human Services, and Education Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff"; Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S. 771 Improving Access to Affordable Prescription Drugs Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
2018 Congressional trade agenda generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
TRICARE pharmacy benefit in P.L. 115-232, the John S. McCain National Defense Authorization Act for Fiscal Year 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to inbound investment in H.R. 4311/S. 2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 21, 2018.
Original Filing: 300993697.xml
Lobbying Issues
General diabetes prevention; World Hemophilia Day; medication affordability and access; H.E.4978/S. 2410, Chronic Disease Management Act of 2018; Growth Awareness Week 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations), and FY19 Labor, Health and Human Services, and Education Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 including coverage gap ("donut hole") access and averting catastrophic coverage Out of Pocket (OOP) "cliff"; Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S. 771 Improving Access to Affordable Prescription Drugs Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
2018 Congressional trade agenda generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
TRICARE pharmacy benefit P.L. 115-232, the John S. McCain National Defense Authorization Act for Fiscal Year 2019.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to inbound investment in H.R.4311/S.2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 20, 2018.
Original Filing: 300978305.xml
Lobbying Issues
General diabetes prevention; World Hemophilia Day; medication affordability and access; H.E.4978/S. 2410, Chronic Disease Management Act of 2018.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEALTHY KIDS Act (CHIP Reauthorization).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S. 771 Improving Access to Affordable Prescription Drugs Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
2018 Congressional trade agenda generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
TRICARE pharmacy benefit in National Defense Authorization Act (NDAA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to inbound investment in H.R.4311/S.2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 20, 2018.
Original Filing: 300956515.xml
Lobbying Issues
General diabetes prevention; World Hemophilia Day.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D included in Section 53116 of H.R. 1892 (Pub. L. 115-123), Bipartisan Budget Act and H.R. 1625 (Pub. L. 115-141), Consolidated Appropriations Act; H.R. 849/S. 260 Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEATHY KIDS Act (CHIP Reauthorization).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Implementation of Pub. L. 115-97 (H.R. 1, Tax Cuts and Jobs Act).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S. 771 Improving Access to Affordable Prescription Drugs Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
2018 Congressional trade agenda generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
TRICARE pharmacy benefit in National Defense Authorization Act (NDAA).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to inbound investment in H.R.4311/S.2098 Foreign Investment Risk Review Modernization Act of 2017 (CFIUS Reform).
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 22, 2018.
Original Filing: 300934686.xml
Lobbying Issues
General diabetes prevention; P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; H.R. 1628 American Health Care Act (AHCA) and Better Care Reconciliation Act of 2017; World Hemophilia Day; Growth Awareness Week; H. Res. 142 and S. Res. 63/S. Res. 325 (A resolution) expressing support for designation of the week of October 29 through November 4, 2017, as "National Obesity Care Week".
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2953/S. 2164, Preventive Health Savings Act (CBO scoring of preventive health); National Diabetes Prevention Program and other CDC diabetes prevention activities in P.L. 115-96 (CR of FY18 Labor, Health and Human Services, and Education Appropriations).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D; H.R. 849/S. 260 Protecting Seniors' Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 3921 HEATHY KIDS Act (CHIP Reauthorization).
Agencies Lobbied
U.S. Senate
Lobbying Issues
P.L. 115-97 (H.R. 1 Tax Cuts and Jobs Act) including Orphan Drug Tax Credit (ODTC), Base Erosion Anti-Abuse Act (BEAT), earlier border adjustment tax proposals and interest deductibility provisions.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S. 771 Improving Access to Affordable Prescription Drugs Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
2017 Congressional trade agenda generally.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
TRICARE pharmacy benefit in P.L. 115-91 H.R. 2810 FY18 National Defense Authorization Act (NDAA).
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914677.xml
Lobbying Issues
General diabetes prevention; H.R. 309/S. 920 Clinical Care Commission Act; H.R. 1628 American Health Care Act (AHCA) and Better Care Reconciliation Act of 2017; World Hemophilia Day; Growth Awareness Week; National Obesity Care Week, H.Res. 142/S.Res. 63; H.R. 3921 Healthy Kids Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2953, To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings; National Diabetes Prevention Program and other CDC diabetes prevention activities in FY 2018 Labor, Health and Human Services, and Education Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D; H.R. 849/S. 260 Protecting Seniors Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 1542 Helping Ensure Life- and Limb-Saving Access to Podiatric Physicians Act (HELLPP Act).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive corporate tax reform, including border adjustment tax and interest deductibility.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 20, 2017.
Original Filing: 300895086.xml
Lobbying Issues
General diabetes prevention; H.R. 309/S. 920 Clinical Care Commission Act; H.R. 1628 American Health Care Act (AHCA) and Better Care Reconciliation Act of 2017; World Hemophilia Day.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.2953, To amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings; National Diabetes Prevention Program and other CDC diabetes prevention activities in FY 2018 Labor, Health and Human Services, and Education Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Diabetes Prevention Program; diabetes self-management education; H.R. 3124/S. 1299/Preventing Diabetes in Medicare Act; H.R. 1953/S. 830 Treat and Reduce Obesity Act; Issues related to Medicare Part D; H.R. 849/S. 260 Protecting Seniors Access to Medicare Act of 2017 and S. 251 Protecting Medicare from Executive Action Act of 2017 (IPAB Repeal); H.R. 1542 Helping Ensure Life- and Limb-Saving Access to Podiatric Physicians Act (HELLPP Act).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Comprehensive corporate tax reform, including border adjustment tax and interest deductibility.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to H.R. 2430/S. 934 FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 20, 2017.
Original Filing: 300875548.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; cost of diabetes generally; H.R. 309, National Clinical Care Commission Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 1953 and S. 830 Treat and Reduce Obesity Act; Medicare diabetes screening generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to H.R. 1628, American Health Care Act, Section 221.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2016
In Q4, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 23, 2017.
Original Filing: 300855740.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing; H.R. 6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations; H.R. 3660 Preventive Health Savings Act, S. 3126 A bill to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Medicare diabetes screening generally; H.R. 2005 and S. 1083 Medicare Drug Savings Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to corporate tax inversion generally.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2016
In Q3, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 20, 2016.
Original Filing: 300837475.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations; Issues related to Medicare Part D, in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act, S. 3126 A bill to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; Protecting Americans from Tax Hikes Act of 2015 (PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2016
In Q2, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $70,000. The report was filed on July 20, 2016.
Original Filing: 300818927.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations, P.L. 114-113 FY16 Consolidated Appropriations, and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act, S. 3126 A bill to amend the Congressional Budget Act of 1974 respecting the scoring of preventive health savings.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; Protecting Americans from Tax Hikes Act of 2015 (PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2016
In Q1, ALSTON & BIRD LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 20, 2016.
Original Filing: 300799268.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to National Diabetes Prevention Program. FY17 Labor/HHS/Education Appropriations, P.L. 114-113 FY16 Consolidated Appropriations, and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; Protecting Americans from Tax Hikes Act of 2015 (PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2015
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 19, 2016.
Original Filing: 300777035.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to National Diabetes Prevention Program in H.R. 3020 and S.1695 FY16 Labor/HHS/Education Appropriations, P.L. 114-113 FY16 Consolidated Appropriations, and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; Protecting Americans from Tax Hikes Act of 2015 (PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization).
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2015
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 20, 2015.
Original Filing: 300764782.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under Pub. L. 111-148, the Patient Protection and Affordable Care Act of 2009 (ACA) and Pub. L. 111-152, the Health Care and Education Affordability Reconciliation Act of 2010; Issues related to diabetes generally; H.R. 1192/S.586, the National Diabetes Clinical Care Commission Act; H.R. 8, the American Taxpayer Relief Act(Special Diabetes Program reauthorization); The Protecting Seniors' Access to Medicare Act of 2016(H.R. 1190/S. 141)(IPAB repeal); H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
National Diabetes Prevention Program; FY16 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare Part D and Medicaid rebates as contained in Pub. L. 112-25, the Budget Control Act of 2011 and H.R. 8, the American Taxpayer Relief Act of 2012; Medicare diabetes screening generally; H.R. 6, 21st Century Cures Act; Treat and Reduce Obesity Act (H.R. 2404/S. 1509); H.R. 2102/S.1131, the Medicare Diabetes Prevention Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Corporate tax inversions.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Transatlantic Trade and Investment Partnership (TTIP) as it relates to intellectual property; Trade Promotion Authority (H.R. 1890/S. 995/H.R.1295/H.R.1267)
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2015
In Q2, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 19, 2015.
Original Filing: 300740156.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under Pub. L. 111-148, the Patient Protection and Affordable Care Act of 2009 (ACA) and Pub. L. 111-152, the Health Care and Education Affordability Reconciliation Act of 2010;
Issues related to diabetes generally; The National Diabetes Clinical Care Commission Act; H.R. 8, the American Taxpayer Relief Act(Special Diabetes Program reauthorization); The Protecting Seniors' Access to Medicare Act of 2016(H.R. 1190/S. 141)(IPAB repeal).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Preventive Health Savings Act (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY16 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015; Issues related to Medicare Part D and Medicaid rebates as contained in Pub. L. 112-25, the Budget Control Act of 2011 and H.R. 8, the American Taxpayer Relief Act of 2012; Medicare diabetes screening generally; H.R. 6, 21st Century Cures Act; Treat and Reduce Obesity Act (H.R. 2404/S. 1509)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Corporate tax inversions.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Transatlantic Trade and Investment Partnership (TTIP) as it relates to intellectual property; Trade Promotion Authority (H.R. 1890/S. 995/H.R.1295/H.R.1267)
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2015
In Q1, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 19, 2015.
Original Filing: 300721136.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under Pub. L. 111-148, the Patient Protection and Affordable Care Act of 2009 (ACA) and Pub. L. 111-152, the Health Care and Education Affordability Reconciliation Act of 2010;
Issues related to diabetes generally; The National Diabetes Clinical Care Commission Act; H.R. 8, the American Taxpayer Relief Act(Special Diabetes Program reauthorization); The Protecting Seniors' Access to Medicare Act of 2013(IPAB repeal).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The Preventive Health Savings Act (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY16 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2, the Medicare Access and CHIP Reauthorization Act of 2015; Issues related to Medicare Part D and Medicaid rebates as contained in Pub. L. 112-25, the Budget Control Act of 2011 and H.R. 8, the American Taxpayer Relief Act of 2012; Medicare diabetes screening generally.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Corporate tax inversions.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Transatlantic Trade and Investment Partnership (TTIP) as it relates to intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2014
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 16, 2015.
Original Filing: 300699243.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under Pub. L. 111-148, the Patient Protection and Affordable Care Act of 2009 (ACA) and Pub. L. 111-152, the Health Care and Education Affordability Reconciliation Act of 2010; Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting ("Catalyst for Better Diabetes"); H.R. 1074 and S. 539, the National Diabetes Clinical Care Commission Act of 2013; H.R. 8, the American Taxpayer Relief Act(Special Diabetes Program reauthorization); H.R. 351 and S. 351, the Protecting Seniors'Access to Medicare Act of 2013 (IPAB repeal); Diabetes screening recommendations under USPSTF.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2663 and S. 1422, the Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY15 Labor/HHS/Education Appropriations (National Diabetes Prevention Program); P.L. 113-235, the Consolidated and Further Continuing Appropriations Act, 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 962 and S. 452, the Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in Pub. L. 112-25, the Budget Control Act of 2011 and H.R. 8, the American Taxpayer Relief Act of 2012; H.R. 1588 and S. 740, the Medicare Drug Savings Act of 2013; H.R. 1257, the Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S. 945, the Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally; diabetes screening recommendations under USPSTF.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 8, the American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023, the Global Investment in American Jobs Act of 2013; corporate tax inversions.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Transatlantic Trade and Investment Partnership (TTIP) as it relates to intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2014
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $70,000. The report was filed on Oct. 17, 2014.
Original Filing: 300681381.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under Pub. L. 111-148, the Patient Protection and Affordable Care Act of 2009 (ACA) and Pub. L. 111-152, the Health Care and Education Affordability Reconciliation Act of 2010; Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting ("Catalyst for Better Diabetes"); H.R. 1074 and S. 539, the National Diabetes Clinical Care Commission Act of 2013; H.R. 8, the American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 351 and S. 351, the Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal); Diabetes screening recommendations under USPSTF.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2663 and S. 1422, the Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY15 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452, the Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in Pub. L. 112-25, the Budget Control Act of 2011 and H.R. 8, the American Taxpayer Relief Act of 2012; H.R. 1588 and S. 740, the Medicare Drug Savings Act of 2013; H.R. 1257, the Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S. 945, the Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally; diabetes screening recommendations under USPSTF.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8, the American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023, the Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
ALSTON & BIRD, LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q22014 on July 29, 2014.
Original Filing: 300671126.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2663 and S. 1422 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY15 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8 American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023 Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 10, 2014.
Original Filing: 300655001.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2663 and S. 1422 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY15 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8 American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023 Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 21, 2014.
Original Filing: 300648762.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2663 and S. 1422 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; FY15 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8 American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023 Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 21, 2014.
Original Filing: 300626246.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; S.RES.242 and H.RES.313 Supporting the goals and ideals of "Growth Awareness Week" and the MAGIC Foundation; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3204 Drug Quality and Security Act, H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8; FY14 Senate Budget Resolution; H Con Res. 25 House Budget Resolution; H.R. 2663 and S. 1422 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013; FY14 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).H.J. Res. 59, FY14 Continuing Appropriations Resolution (contains "Bipartisan Budget Act of 2013").
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8 American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023 Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 21, 2013.
Original Filing: 300607382.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes); H.R. 1074 and S. 539 National Diabetes Clinical Care Commission Act of 2013; S.RES.242 and H.RES.313 Supporting the goals and ideals of "Growth Awareness Week" and the MAGIC Foundation; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; H.R. 351 and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3204 Drug Quality and Security Act, H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8; FY14 Senate Budget Resolution; H Con Res. 25 House Budget Resolution; H.R. 2663 and S. 1422 The Preventative Health Savings Act of 2013 (Modernizing CBO scoring with respect to preventive health legislation); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013; FY14 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 and S 945 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8 American Taxpayer Relief Act (R&D tax credit) of 2012; H.R. 2052 and S. 1023 Global Investment in American Jobs Act of 2013.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
ALSTON & BIRD LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q22013 on March 22, 2017.
Original Filing: 300861758.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), H.R. 1074 and S 539 National Diabetes Clinical Care Commission Act of 2013; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8; FY14 Senate Budget Resolution; H Con Res. 25 House Budget Resolution; H.R. 2633 The Preventative Health Savings Act of 2013 (Modernizing cost estimates with respect to CBO scoring preventive health legislation); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013; FY14 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8, American Taxpayer Relief Act (R&D tax credit) of 2012.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 22, 2013.
Original Filing: 300586007.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), H.R. 1074 and S 539 National Diabetes Clinical Care Commission Act of 2013; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); H.R. 1915 and S. 907 Gestational Diabetes Act of 2013; and S. 351 Protecting Seniors' Access to Medicare Act of 2013 (IPAB repeal).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1919 Safeguarding America's Pharmaceuticals Act of 2013 and S.959 Pharmaceutical Compounding Quality and Accountability Act (for track and trace supply chain provisions).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8; FY14 Senate Budget Resolution; H Con Res. 25 House Budget Resolution; H.R. 2633 The Preventative Health Savings Act of 2013 (Modernizing cost estimates with respect to CBO scoring preventive health legislation); National Diabetes Prevention Program; HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013; FY14 Labor/HHS/Education Appropriations (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 1588 & S. 740 Medicare Drug Savings Act of 2013; H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8, American Taxpayer Relief Act (R&D tax credit) of 2012.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 22, 2013.
Original Filing: 300563663.xml
Lobbying Issues
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), Prevention and Public Health Fund, and USPSTF diabetes screening standards;H.R. 1074 and S 539 Diabetes Clinical Care Commission Act of 2013; human growth / rare disorders awareness; H.R. 8 American Taxpayer Relief Act (Special Diabetes Program reauthorization); gestational diabetes; H.R. 351 and S. 351 IPAB Repeal of 2013.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues regarding Pharmaceutical Traceability Enhancement Code (Rx TEC) Act and discussion draft on serialization (track and trace).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D, FDA and patents in S. Con. Res. 8 FY14 Senate Budget Resolution; Modernizing cost estimates with respect to preventive health legislation (CBO scoring); National Diabetes Prevention Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25 Budget Control Act of 2011 and H.R. 8 American Taxpayer Relief Act of 2012; H.R. 962 and S. 452 Medicare Diabetes Prevention Act of 2013; H.R. 1257 Preventing Diabetes in Medicare Act of 2013 and prediabetes generally; H.R. 1274 Access to Quality Diabetes Education Act of 2013 (Diabetes Self-Management Training in Medicare); Medicare diabetes screening generally.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 8, American Taxpayer Relief Act (R&D tax credit) of 2012.
Agencies Lobbied
U.S. House of Representatives,
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2012
ALSTON & BIRD, LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q42012 on March 22, 2013.
Original Filing: 300546628.xml
Lobbying Issues
Supporting increasing funding opportunities for better care and treatment of people with diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program; Special Diabetes Programs reauthorization; National Prevention Strategy; Prevention and Public Health Fund; S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program); H.R. 8, American Taxpayer Relief Act (special diabetes program reauthorization)>
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 3187, FDA Safety and Innovation Act; H.R. 4274, Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act; H.R. 1513/S. 810, Great Apes Protection Act; Pharmaceutical Traceability Enhancement Code (RxTEC) Act and draft legislation on downstream supply chain safety/serialization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6482, The Preventative Health Savings Act of 2012 (modernizing cost estimates with respect to preventative health and legislation (scoring)); S. 3463/H.R. 6548, National Diabetes Prevention Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Medicare Diabetes Screening; H.R. 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25, Budget Control Act of 2011 (deficit reduction); S. 3463/H.R. 6548, Medicare Diabetes Prevention Act of 2012.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 22, 2013.
Original Filing: 300542059.xml
Lobbying Issues
Supporting increasing funding opportunities for better care and treatment of people with diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program; Special Diabetes Programs reauthorization; National Prevention Strategy; Prevention and Public Health Fund; S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program); H.R. 8, American Taxpayer Relief Act (special diabetes program reauthorization)>
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 3187, FDA Safety and Innovation Act; H.R. 4274, Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act; H.R. 1513/S. 810, Great Apes Protection Act; Pharmaceutical Traceability Enhancement Code (RxTEC) Act and draft legislation on downstream supply chain safety/serialization.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6482, The Preventative Health Savings Act of 2012 (modernizing cost estimates with respect to preventative health and legislation (scoring)); S. 3463/H.R. 6548, National Diabetes Prevention Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Medicare Diabetes Screening; H.R. 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25, Budget Control Act of 2011 (deficit reduction); S. 3463/H.R. 6548, Medicare Diabetes Prevention Act of 2012.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 22, 2012.
Original Filing: 300521131.xml
Lobbying Issues
Supporting increasing funding opportunities for better care and treatment of people with diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program; Special Diabetes Programs reauthorization; National Prevention Strategy; Prevention and Public Health Fund; S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 3187, FDA Safety and Innovation Act; H.R. 4274, Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6482, The Preventative Health Savings Act of 2012 (modernizing cost estimates with respect to preventative health and legislation (scoring)); S. 3463/H.R. 6548, National Diabetes Prevention Program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Medicare Diabetes Screening; H.R. 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25, Budget Control Act of 2011 (deficit reduction); S. 3463/H.R. 6548, Medicare Diabetes Prevention Act of 2012.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 20, 2012.
Original Filing: 300497844.xml
Lobbying Issues
Supporting increasing funding opportunities for better care and treatment of people wiht diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program; Special Diabetes Programs reauthorization; National Prevention Strategy; Prevention and Public Health Fund; S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2013 (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 3187, FDA Safety and Innovation Act; H.R. 4274, Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to modernizing cost estimates with respect to preventive health legislation (scoring).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010 (HCERA); Medicare Diabetes Screening; H.R. 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes enerally; Issues related to Medicare Part D and Medicaid rebates as contained in P.L. 112-25, Budget Control Act of 2011 (deficit reduction)
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2012
In Q1, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 20, 2012.
Original Filing: 300474991.xml
Lobbying Issues
Supporting increasing funding opportunities for better care and treatment of people wiht diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program; National Prevention Strategy; P.L. 112-77, Consolidates Appropriations Act of 2012 (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid rebates and similar revenue provisions as contained in P.L. 112-25, Budget Control Act of 2011 (deficit reduction).
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2011
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 20, 2012.
Original Filing: 300452779.xml
Lobbying Issues
Supporting increasing funding opportunities for better care and treatment of people wiht diabetes in P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program; National Prevention Strategy; P.L. 112-77, Consolidates Appropriations Act of 2012 (National Diabetes Prevention Program).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid rebates and similar revenue provisions as contained in P.L. 112-25, Budget Control Act of 2011 (deficit reduction).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2112, Fiscal Year 2012 Agriculture, Commerce-Justice-Science, Transportation-HUD Appropriations, prescription drug reimportation.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2011
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 20, 2011.
Original Filing: 300429377.xml
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 & P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010, issues related to diabetes generally, diabetes screening and minority health.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to diabetes programs and prevention funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid rebates and similar revenue provisions as contained in P.L. 112-25, Budget Control Act of 2011; P.L. 111-148, Patient Protection and Affordable Care Act of 2009; P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; American Jobs and Closing Tax Loopholes Act of 2010; and Jobs Creation and Tax Cut Act; and Continuing Appropriations Act 2011, issues related to the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2011
In Q2, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 20, 2011.
Original Filing: 300405847.xml
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 & P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010, issues related to diabetes generally, diabetes screening and minority health.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to diabetes programs and prevention funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid rebates and similar revenue provisions as contained in P.L. 111-148, Patient Protection and Affordable Care Act of 2009; P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; American Jobs and Closing Tax Loopholes Act of 2010; and Jobs Creation and Tax Cut Act; and Continuing Appropriations Act 2011, issues related to the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2011
In Q1, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 20, 2011.
Original Filing: 300380072.xml
Lobbying Issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 & P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010, issues related to diabetes generally, diabetes screening and minority health.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues relating to diabetes programs and prevention funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid rebates and similar revenue provisions as contained in P.L. 111-148, Patient Protection and Affordable Care Act of 2009; P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; American Jobs and Closing Tax Loopholes Act of 2010; and Jobs Creation and Tax Cut Act; and Continuing Appropriations Act 2011, issues related to the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2010
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 20, 2011.
Original Filing: 300354805.xml
Lobbying Issues
S 844/HR 1995 Eliminating Disparities in Diabetes Prevention and Care Act; HR 5354 - The Gestational Diabetes Act; P.L. 111-148, Patient Protection and Affordable Care Act of 2009; P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010, issues related to diabetes and minority health; H.R, 6012, the Diabetes Screening Utilization Act; H.R. 5354, Gestational Diabetes Act (GEDI); H.R. 2590, Preventing Diabetes Medicare Act; H.R. 2425, Medicare Diabetes Self-Management Training Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5175 - the DISCLOSE Act
Lobbying Issues
H.R. 3663 and S. 3058, To amend the Public Health Service Act to reauthorize the special diabetes programs for Type 1 diabetes and Indians under that Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Medicaid rebates and similar revenue provisions as contained in P.L. 111-148, Patient Protection and Affordable Care Act of 2009; P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010; H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010; and S. 3793, Jobs Creation and Tax Cut Act; and H.R. 3081, Continuing Appropriations Act 2011, issues related to the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 20, 2010.
Original Filing: 300329133.xml
Lobbying Issues
S 1473/HR 1402 Bipartisan Catalyst to Better Diabetes Care Act; S 844/HR 1995 Eliminating Disparities in Diabetes Prevention and Care Act; HR 5354 - The Gestational Diabetes Act; HR 3668/S 3058 - Special Diabetes Program for Type I and Indians.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4899-provisions relating to pharmaceuticals; H.R. 4213-provisions relating to pharmaceutical pricing; H.R. 6012-utilization of Medicare diabetes screening benefit.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5175 - the DISCLOSE Act
2nd Quarter, 2010
In Q2, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on July 20, 2010.
Original Filing: 300303397.xml
Lobbying Issues
S 1473/HR 1402 Bipartisan Catalyst to Better Diabetes Care Act; S 844/HR 1995 Eliminating Disparities in Diabetes Prevention and Care Act; and diabetes research, prevention and care program funding.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4899, H.R. 4213 - provisions relating to pharmaceutical pricing
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5175 - the DISCLOSE Act
1st Quarter, 2010
In Q1, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on April 20, 2010.
Original Filing: 300275038.xml
Lobbying Issues
Health Care reform proposals in the House and Senate - Issues concerning the prevention and treatment of diabetes,
S. 1473/H.R. 1402 - Bipartisan Catalyst to Better Daibetes Care Act; S. 844/H.R. 1995 - Eliminating Disparities in Diabetes Prevention and Care Act; H.R. 3590 - Patient Protection and Affordable Care Act; H.R. 3962 - Affordable Health Care for America Act; H.R. 4872 - Health Care and Education Reconciliation Act of 2010, section 2302
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2009
In Q4, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Jan. 20, 2010.
Original Filing: 300248133.xml
Lobbying Issues
Health Care reform proposals in the House and Senate - Issues concerning the prevention and treatment of diabetes,
S. 1473/H.R. 1402 - Bipartisan Catalyst to Better Daibetes Care Act; S. 844/H.R. 1995 - Eliminating Disparities in Diabetes Prevention and Care Act; H.R. 3590 - Patient Protection and Affordable Care Act (Amendment #2793); H.R. 3962 - Affordable Health Care for America Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
ALSTON & BIRD, LLP amended a lobbying report for representation of Novo Nordisk Inc. in Q32009 on Oct. 21, 2009.
Original Filing: 300222866.xml
Lobbying Issues
Health care reform proposals in the House and Senate
Issues concerning the prevention and treatment of diabetes
S. 1473/H.R. 1402, Bipartisan Catalyst to Better Diabetes Care Act
S. 844/H.R. 1995, Eliminating Disparaties in Diabetes Prevention and Care ActHR 2590, Preventing Diabetes in Medicare Act
HR 3148, The Preventive Health Savings Act of 2009
HR 2425, Medicare Diabetes Self-Management Training Act
HR 3200, America's Affordable Health Choices Act of 2009
S. ___ America's Healthy Future Act (Senate Finance Committee health reform proposal)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
In Q3, ALSTON & BIRD, LLP lobbied for Novo Nordisk Inc. , earning $60,000. The report was filed on Oct. 20, 2009.
Original Filing: 300222265.xml
Lobbying Issues
Health care reform proposals in the House and Senate
Issues concerning the prevention and treatment of diabetes
S. 1473/H.R. 1402, Bipartisan Catalyst to Better Diabetes Care Act
S. 844/H.R. 1995, Eliminating Disparaties in Diabetes Prevention and Care ActHR 2590, Preventing Diabetes in Medicare Act
HR 3148, The Preventive Health Savings Act of 2009
HR 2425, Medicare Diabetes Self-Management Training Act
HR 3200, America's Affordable Health Choices Act of 2009
S. ___ America's Healthy Future Act (Senate Finance Committee health reform proposal)
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2009
ALSTON & BIRD, LLP filed a lobbying registration on Aug. 5, 2009 to represent Novo Nordisk Inc., effective July 16, 2009.
Original Filing: 300196886.xml
Issue(s) they said they’d lobby about: Health care reform proposals in the House and Senate
Issues concerning the prevention and treatment of diabetes. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...